Geron Co. (NASDAQ:GERN - Free Report) - Stock analysts at B. Riley lifted their FY2026 earnings estimates for Geron in a research report issued on Thursday, November 7th. B. Riley analyst K. Patel now forecasts that the biopharmaceutical company will post earnings per share of $0.19 for the year, up from their previous forecast of $0.15. The consensus estimate for Geron's current full-year earnings is ($0.34) per share.
Geron (NASDAQ:GERN - Get Free Report) last posted its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported ($0.04) EPS for the quarter, topping the consensus estimate of ($0.09) by $0.05. Geron had a negative net margin of 682.48% and a negative return on equity of 67.10%. The business had revenue of $28.27 million for the quarter, compared to analyst estimates of $18.97 million. During the same quarter in the previous year, the firm posted ($0.08) earnings per share. Geron's quarterly revenue was up 17138.4% on a year-over-year basis.
Several other brokerages have also recently issued reports on GERN. HC Wainwright initiated coverage on shares of Geron in a report on Tuesday, November 5th. They issued a "buy" rating and a $8.00 target price for the company. Leerink Partners started coverage on shares of Geron in a research note on Monday, September 9th. They issued an "outperform" rating and a $7.00 price target for the company. Leerink Partnrs upgraded shares of Geron to a "strong-buy" rating in a research report on Monday, September 9th. Needham & Company LLC reissued a "buy" rating and issued a $6.00 price objective on shares of Geron in a report on Friday, August 9th. Finally, Wedbush restated an "outperform" rating and issued a $8.00 price target on shares of Geron in a research report on Thursday, August 8th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $7.05.
Get Our Latest Stock Report on GERN
Geron Trading Down 3.1 %
Shares of NASDAQ:GERN traded down $0.13 on Monday, hitting $4.12. 8,311,319 shares of the company traded hands, compared to its average volume of 10,453,094. Geron has a 52 week low of $1.64 and a 52 week high of $5.34. The stock has a 50 day simple moving average of $4.31 and a 200-day simple moving average of $4.32. The company has a debt-to-equity ratio of 0.12, a current ratio of 3.61 and a quick ratio of 3.60.
Institutional Investors Weigh In On Geron
A number of hedge funds have recently made changes to their positions in GERN. Darwin Global Management Ltd. bought a new stake in Geron in the second quarter worth $106,185,000. Renaissance Technologies LLC purchased a new position in shares of Geron during the second quarter valued at $3,315,000. Price T Rowe Associates Inc. MD raised its holdings in shares of Geron by 999.7% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 2,064,963 shares of the biopharmaceutical company's stock valued at $6,815,000 after purchasing an additional 1,877,184 shares in the last quarter. Algert Global LLC purchased a new stake in Geron during the second quarter worth $539,000. Finally, Farallon Capital Management LLC boosted its position in Geron by 124.6% during the second quarter. Farallon Capital Management LLC now owns 16,837,000 shares of the biopharmaceutical company's stock valued at $71,389,000 after purchasing an additional 9,342,000 shares in the last quarter. 73.71% of the stock is currently owned by hedge funds and other institutional investors.
About Geron
(
Get Free Report)
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.
Recommended Stories
Before you consider Geron, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Geron wasn't on the list.
While Geron currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Keep reading to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
